Created by Mike Fraser
Comprehensive market, consumer, and investment data for anti-aging biopharma
Explore the latest content tracked by Anti-Aging Biopharma Tracker
Key clinical milestone: RJx-01 demonstrates strong safety and efficacy in human sarcopenia studies with disease-modifying action; Phase 2b readouts...
Genomics evolves into infrastructure via AI convergence, unlocking new business models from falling sequencing costs.
Emerging VC trend in anti-aging biopharma:
EyePoint Pharmaceuticals shares up nearly 100% in a year after drawing a new $20M investment to advance DURAVYU, a sustained-release therapy for wet AMD and serious retinal diseases. Key signal of capital flowing into age-related eye biopharma.
Emerging policy shifts in peptides and hormones fuel market formation through uncertainty.
Breakthrough potential in Alzheimer's therapy: Current AD treatments are ineffective, but NGF-modified hair follicle stem cells enable brain regeneration via transplantation, overcoming limited stem sources.
Preclinical breakthrough: Immorta Bio's SenoVax (senolytic vaccine) + StemCellRevivify (stem cells) doubled lifespan in doxorubicin-induced senescent...
Payer breakthrough for metabolic pharma in Medicare: CMS's GLP-1 Bridge Model starts July 1, 2026, offering eligible beneficiaries drugs like Zepbound...
Germany's emerging framework supports longevity innovations via targeted IP and regulatory strategies:
Strategic AI collab boosts efficiency in anti-aging biopharma R&D:
Cognito Therapeutics closed an oversubscribed $105M Series C to advance its neurodegenerative disease programs, highlighting sustained investor interest amid biotech funding pressures—a key capital flow into aging-relevant 60+ interventions.
Key GMP milestone for regenerative longevity: Avaí Bio and Austrianova initiate production of Master Cell Bank from α-Klotho-overexpressing cells.
-...
Emerging senolytic trends target senescent cells in age-related bone fragility:
Key payer and affordability signals for semaglutide in secondary CVD prevention (post-MI/stroke patients):
